HGS has substantial financial rights to three products in the GSK clinical development pipeline. Two of these are genomics-derived small-molecule drugs discovered by GSK based on HGS technology. The third product is an albumin-fusion protein created by HGS.

Darapladib is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that has been identified in clinical trials as an independent risk factor for coronary heart disease and ischemic stroke. GSK has advanced darapladib to Phase 2/3 clinical trials for the treatment of atherosclerosis. Darapladib was discovered by GSK based on HGS technology, and it has the potential to be an important new treatment for the prevention of cardiovascular risk.

Syncria® (albiglutide) is a novel longer-acting form of glucagon-like peptide-1 (GLP-1). GLP-1 is a peptide hormone that acts to help maintain healthy blood sugar levels and to control appetite. Syncria was created using the HGS proprietary albumin fusion technology, and was licensed to GSK in October 2004. In May 2007, GSK initiated a Phase 2b randomized dose-ranging trial of Syncria in patients with type 2 diabetes.

GSK649868 is a small-molecule orexin antagonist. Orexin is a hormone that plays an important role in the regulation of sleep-wake cycles. GSK649868 is in Phase 2 clinical development for the treatment of sleep disorders.

For additional information about any of the GSK products to which HGS has rights, please contact GSK directly.